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A tobacco mosaic virus (TMV)-based vector has been used to express in plants the complete open reading frame coding
for VP1, the major immunogenic protein of foot and mouth disease virus (FMDV). In vitro RNA transcripts were inoculated into
Nicotiana benthamiana plants and detectable amounts of recombinant VP1 were identified by Western blot as soon as 4 days
postinfection. Foliar extracts prepared from infected leaves were injected intraperitoneally into mice and all of the immunized
animals developed a specific antibody response to both the complete virus particle and the major immunogenic region as
determined by ELISA and Western blot analysis. Most importantly, all immunized mice developed a protective immune
response against experimental challenge with virulent FMDV. To our knowledge, this is the first report showing the
expression of a complete open reading frame of an antigenic foreign protein in plants, using a recombinant plant virus, in
sufficient quantity to permit use of the crude plant extract as an experimental immunogen to protect animals against virus
challenge. © 1999 Academic PressKey Words: FMDV; infectious immunity—virus; vaccination; TMV.
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iINTRODUCTION
The use of plants as systems for expression of foreign
ntigens has been increasingly evaluated as an inexpen-
ive alternative to conventional fermentation systems for
accine production (Arntzen and Mason, 1995). Trans-
enic plants have been employed to express a variety of
iral and bacterial antigens which have been used suc-
essfully as experimental immunogens either by paren-
eral inoculation or by oral administration (Arakawa et al.,
998; Haq et al., 1995; Mason et al., 1992, 1996, 1998;
cGarvey et al., 1995; Tacket et al., 1998). We have
ecently described the utilization of transgenic plants for
he production of foreign proteins for use as experimen-
al vaccines (Carrillo et al., 1998; Go´mez et al., 1998;
igdorovitz et al., 1999). The limitation, in most cases, is
hat the amount of the expressed antigen in the trans-
enic plants is too low to be routinely useful for practical
roduction of vaccine antigens. Consequently, although
e have successfully demonstrated that a foot and
outh disease virus (FMDV) structural protein, VP1,
ould be expressed as an immunogenic antigen in both
rabidopsis and alfalfa (Carrillo et al., 1998; Wigdorovitz
t al., 1999), in both cases the yield of the recombinant
1 These authors contributed equally to the results presented in this
eport.
2 To whom correspondence and reprint requests should be ad-
ressed. Fax: 54-11-4621-1743. E-mail: mborca@cicv.inta.gov.ar.
85ntigen was very low. The low yield of product consti-
utes a practical disadvantage for the implementation of
his technology because additional purification steps
ould be needed to concentrate the antigen of interest.
his remains an important problem for practical applica-
ion of this technology.
The expression of foreign antigens in plants using
ecombinant plant viruses as vectors has provided an
lternative approach for foreign gene expression that
as generally resulted in the production of higher quan-
ities of the foreign protein of interest (Dalsgaard et al.,
997; Joelson et al., 1997; Porta et al., 1994, 1996; Turpen
t al., 1995; Usha et al., 1993; Yusibov et al., 1997).
owever, the reported applications of the use of viral
ectors to express antigenic proteins have primarily
een limited to the detection of the product of the recom-
inant virus and analysis of the antigenicity of the ex-
ressed foreign epitope after isolation from the plant
issue. Only the most recent reports from Yusibov et al.
1997), eliciting neutralizing antibodies against discrete
pitopes of HIV and rabies virus using tobacco mosaic
irus (TMV) as a vector and, in particular, from Dalsgaard
t al. (1997), who expressed an epitope of the mink
nteritis virus on the surface of cowpea mosaic virus
CPMV), protecting animals against the experimental
hallenge, actually demonstrated that the plant-pro-
uced antigen could be effective at eliciting a significant
mmune response.
FMDV is the causative agent of an economically im-
0042-6822/99 $30.00
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86 WIGDOROVITZ ET AL.ortant disease affecting meat- and milk-producing ani-
als and the comprehensive vaccination of all suscep-
ible hosts constitutes the basis of all sanitary plans for
he control and eradication of the disease (Brown, 1992).
he structural protein VP1 carries critical epitopes re-
ponsible for the induction of neutralizing antibodies and
ts expression in a diversity of systems has been per-
ormed, resulting in effective experimental immunogens
Brown, 1992; DiMarchi et al., 1986; Kleid et al., 1981;
amorano et al., 1994, 1998). We have focused on the
evelopment of alternative methods of FMDV vaccine
roduction in plants with the goal of providing a practical
lternative to the current methodology of vaccine produc-
ion, which is both costly and risky because of manipu-
ation of massive amounts of virulent virus, which could
esult in virulent virus dissemination (Brown, 1992).
ence, we are primarily interested in developing a safe
xpression system that would be cost effective for deliv-
ry on a large scale.
In this regard, we investigated the use of a recombi-
ant TMV vector to express the complete open reading
rame of the VP1 structural protein of FMDV serotype O1
ampos (O1C) in the tobacco host Nicotiana benthami-
FIG. 1. Accumulation of recombinant FMDV VP1 in N. benthamiana p
f plants infected with either TMV.WT or TMV.VP1 was determined by W
f the FMDV O1C VP1. (A) Time course experiment showing the analys
arvested at different times postinoculation. Lane descriptions: lane A
eaves infected with TMV.WT at 4, 6, and 8 dpi; lane E, molecular weight
t 3 through 8 dpi. (B) Western blot of tissue extracts obtained from ino
f N. benthamiana plants at 10 dpi. The plants were either mock inocula
lanes 5 and 6). The blots were developed as described in the text.na. Unlike the previous studies using other plant vi- auses as vectors (Dalsgaard et al., 1997; Joelson et al.,
997; Porta et al., 1994, 1996; Turpen et al., 1995; Usha et
l., 1993; Yusibov et al., 1997), here the FMDV antigen
ould constitute the entire VP1 structural protein and be
xpressed in a soluble form in the plant cells. The results
resented in this report demonstrate that VP1 was rap-
dly produced in detectable amounts in the plant cells
nd that mice parenterally immunized with leaf extracts
eveloped a specific immune response which com-
letely protected the animals against experimental chal-
enge with virulent virus.
RESULTS
xpression of recombinant VP1 in the TMV.VP1-
nfected plants
The accumulation of recombinant FMDV VP1 protein
as initially monitored in a time course experiment in
hich leaf tissue was harvested daily and frozen at
80°C beginning 3 days postinoculation (dpi). Figure 1
hows the results of a typical experiment in which a
pecific band of expected size for the FMDV VP1 (ca. 26
Da) was readily detected in the foliar extracts as soon
nfected with the TMV.VP1 vector. The presence of VP1 in leaf extracts
blot analysis using a mouse serum specific for the p135-160 peptide
ml of crude leaf extracts isolated from the inoculated leaves of plants
extracts from mock-infected leaves; lanes B, C, and D, extracts from
rs; lanes F, G, H, I, J, and K, extracts from leaves infected with TMV.VP1
(lanes 1, 3, and 5) and systemically infected (lanes 2, 4, and 6) leaves
es 1 and 2) or infected with either TMV.WT (lanes 3 and 4) or TMV.VP1lants i
estern
is of 5
, tissue
marke
culated
ted (lans 4 dpi. The results also show that the accumulation of
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87PROTECTIVE IMMUNE RESPONSE TO FMDV IN MICEhe VP1-specific protein peaked at about 7 dpi in the
noculated leaves and declined slightly thereafter. No
eactivity with the FMDV antisera was detected in ex-
racts of either the mock-inoculated or the TMV.WT-in-
ected leaves (Fig. 1A). The VP1 protein also accumu-
ated to similar levels in both inoculated and systemically
nfected leaves of the same plant harvested at 10 dpi
Fig. 1B). In this experiment, smaller forms of the VP1
rotein are evident in the extract from systemic leaves,
uggesting that some proteolytic degradation of the pro-
ein takes place in the plant extracts. Using serial dilu-
ions, and based on the extinction of the signal com-
ared with a known control preparation using purified
MDV particles, it was possible to estimate that the
oncentration of the expressed VP1 in different foliar
xtracts tested ranged between 50 and 150 mg per gram
f freshly harvested leaves (data not shown).
nduction of an anti-FMDV immune response in mice
mmunized with crude leaf extract infected with
MV.VP1
The immunogenicity of the expressed VP1 was ana-
yzed by injection into an experimental host and quanti-
ied in terms of the induction of a FMDV-specific antibody
esponse. Adult male BALB/c mice (60 to 90 days of age)
ere immunized intraperitoneally on days 0, 15, 30, 45,
nd 60 with leaf extracts from plants infected either with
MV.VP1 or with wild-type TMV. Each mouse was immu-
ized with 150 ml of leaf extract containing 15 to 20 mg of
resh leaf tissue (approximately 0.5–1 mg of recombinant
P1) per dose. The first dose was emulsified in complete
reund’s adjuvant and the subsequent booster doses
ere in incomplete Freund’s adjuvant. Ten days after the
ast booster, animals were bled and the sera were ana-
yzed for the presence of anti-FMDV antibodies by ELISA.
The ELISAs showed that all of the mice immunized
ith foliar extracts from leaves infected with TMV.VP1
ad significant titers of antibody directed against the
135-160 epitope of VP1 (Figs. 2A and 2B, white bars). In
ddition, all of the same mouse sera reacted specifically
ith intact FMDV particles in similar assays (black bars).
n contrast, none of the mice immunized with leaf ex-
racts from plants infected with TMV.WT showed any
pecific reactivity by ELISA. The specificity of the anti-
P1 response in the mouse sera was also confirmed by
estern blot analysis. Purified FMDV was subjected to
AGE and three different pools of sera from mice immu-
ized with the plant extracts infected with TMV.VP1 were
ested and shown to respond specifically against the VP1
n the Western blots (Fig. 3). The immunization experi-
ents were independently performed twice (Groups A
nd B in Fig. 2). Together, these results demonstrate that
he VP1 expressed in plants infected with TMV.VP1 was
mmunogenically similar to the native protein on the virus
article. trotection against virus challenge in the immunized
nimals
The efficacy of the plant extract was tested by chal-
enging mice with live FMDV (Figs. 2A and 2B). In two
eparate experiments, the mice were inoculated (ip) with
04 SM50LD of FMDV O1C and examined, at 36 h post-
noculation, for presence or absence of viremia (Table 1).
n both experiments, all the animals immunized with
MV.VP1 extracts failed to show any viremia, indicating
hat they were effectively protected against the chal-
enge. Under the same conditions, none of the 14 ani-
als immunized with extracts from TMV.WT-infected
eaves and none of 12 mock-immunized animals showed
ny protection, succumbing to the typical viremia in the
xpected period after inoculation.
DISCUSSION
The results presented in this report demonstrate that
FIG. 2. Detection of anti-FMDV antibodies in mice after the immuni-
ation with crude leaf extract obtained from plants inoculated with the
MV.VP1 vector. The mouse sera were analyzed for the presence of
nti-FMDV antibodies by ELISA using either the synthetic peptide
135-160 (white bars) or complete FMDV particles (black bars) as
ntigen. The assays were performed essentially as described else-
here (Pe´rez Filgueira et al., 1995) and as outlined briefly in the text.
he results of two independently performed experiments in which 11
ice (top) and 14 mice (bottom) were individually analyzed are shown.
erum titers are expressed as log10 of the reciprocal of the highest
erum dilution which produced OD readings at least 3 standard devi-
tions above the mean OD readings of sera from five animals immu-
ized with plants infected with the control TMV.WT vector. Each pair of
ars corresponds to an individual mouse serum.he FMDV VP1 protein, produced in plants infected with
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88 WIGDOROVITZ ET AL.ecombinant TMV.VP1, induced a significant and specific
mmune response in mice which was able to protect the
nimals from the experimental challenge with virulent
MDV. They also provide evidence that it is possible to
xpress a complete structural protein of an animal virus
s a nonstructural protein in plant cells using a plant
irus vector. The results support the conclusion that the
P1 expressed in TMV.VP1-infected plants possesses
any of the properties of the native viral protein in terms
f both its antigenicity (tested by Western blot) and its
mmunogenicity as analyzed in three independent sero-
ogical tests which detect anti-VP1 antibody activity
gainst native VP1 in different configurations (complete
enatured VP1 by Western blot, VP1 immunodominant
inear epitopes by direct ELISA, and VP1 as part of the
tructure of the virus particle by capture ELISA). In addi-
ion, the fact that the expressed protein was able to
nduce consistently a viral-specific protective response
n all of the parenterally immunized mice tested suggests
hat this expression system may prove to be both a
eliable and an economically viable alternative for pro-
uction of antigen for immunization purposes. The data
resented here were all produced using experimental
onditions and, certainly, much further work is needed in
rder to optimize the methodology. Its practical imple-
entation would provide, as the main advantage, the
limination of all the technical inconveniences related to
he large-scale in vitro fermentation procedures currently
sed in the industry.
Although clear differences exist in the pathology of the
MDV infection in mice and cattle, the immune mecha-
isms that prevent or eliminate the infection as well as
he most relevant viral epitopes mediating the protective
mmune response appear to be quite similar. Thus, it is
xpected that results similar to those presented here in
ice would be obtained by immunizing cattle with ex-
racts from TMV.VP1-infected plants. In fact, preliminary
FIG. 3. Anti-VP1 antibodies detected by Western blot in the sera from
ice immunized intraperitoneally with leaf extracts from TMV-infected
lants. The plant extracts used for immunization were from plants
nfected with TMV.WT (lanes A and B) or TMV.VP1 (lanes C, D, E, and F).
pool of sera from mice immunized with the VP1 peptide p135-160
erved as a control (lane G). Lane H, nonimmune mouse serum. The
ntigen used for the Western blot was purified, inactivated FMDV. The
ouse sera in these analyses consisted of pools from different animals
sed at a dilution of 130.esults obtained in our laboratory indicate that 1-year-old calves immunized with TMV.VP1-infected extracts devel-
ped a significative FMDV-specific antibody response
gainst p135-160, VP1, and complete virus particles
A. Wigdorovitz et al., unpublished results).
In a previous study, Usha et al. (1993) reported on the
xpression of one of the major VP1 epitopes displayed
n the surface of the capsid of CPMV in plants. They
howed that the epitope retained its antigenic properties
hen tested against an anti-FMDV serum but the quan-
ity of virus produced was very limited. In a subsequent
eport (1994), they were able to greatly improve the level
f accumulation of the recombinant epitope of FMDV
P1, although the replication of the recombinant virus
as restricted to the inoculated leaves, with no systemic
nfection in the upper leaves. In neither study did the
uthors evaluate the immunogenicity of the recombinant
irus produced in the plant hosts. Interestingly, the re-
ults presented here showed that, in our system, VP1 is
ynthesized in comparable quantities in both inoculated
nd systemic leaves and that the concentration of the
oreign antigen is maintained at detectable levels for an
xtensive period during the replication of the TMV vector.
We believe this report, along with the one presented
y Dalsgaard et al. (1997), is the first to convincingly
emonstrate the practical application of inducing a pro-
ective immune response against infection with a virulent
nimal pathogen by immunization with an antigen ex-
ressed in plants using a recombinant plant virus. We
hink our system has some significant advantages over
he epitope display system because it allows for accu-
ulation of the entire antigenic protein rather than a
mall epitope of the protein. Also, we believe that we
ave shown for the first time that it is possible to express
complete open reading frame of an antigenic foreign
rotein in plants, using a recombinant plant virus as a
ector, and utilize the crude infected plant extracts as an
xperimental immunogen to protect animals against in-
ection. These results provide data supporting the pos-
ibility that production of reliable vaccines in plants can
ndeed be a very attractive and inexpensive procedure.
TABLE 1
Protection against the FMDV Challenge in Mice Immunized
with Plant Extracts
Leaf extract used in mice
Protection ratea
Experiment A Experiment B
TMV.VP1 infected 14/14 (100%) 16/16 (100%)
TMV.WT infected 0/6 (0%) 0/8 (0%)
Mock 0/6 (0%) 0/6 (0%)
a Protection is expressed as number of protected mice/number of
hallenged mice.
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89PROTECTIVE IMMUNE RESPONSE TO FMDV IN MICEMATERIALS AND METHODS
onstruction of the recombinant TMV.VP1
The recombinant used in these studies was synthe-
ized from a variant of a TMV-30B expression vector
indly provided by Dr. W. O. Dawson (Donson et al., 1991;
umagai et al., 1993). This vector, diagrammed in Fig. 4,
s typical of previously used TMV-based vectors with the
eplicase (RNA-dependent RNA polymerase), movement
rotein (mp), and coat protein (cp) genes of the plant
irus intact. The TMV strain U1 genome was altered by
nsertion of a polylinker sequence just downstream of
he subgenomic promoter that originally controlled tran-
cription of the cp gene. This permitted facile insertion of
he gene of interest such that it would be expressed
nder the control of the subgenomic promoter of the cp
ene. The expression of the viral cp gene itself was
egulated by insertion of a second homologous sub-
enomic promoter derived from a closely related virus
TMV strain U5). This design eliminated the duplicated
p promoter sequence of the previous TMV vectors and
educed the instability of the foreign gene inserts in the
ector (Donson et al., 1991; Kumagai et al., 1993).
The VP1 gene was obtained by PCR amplification from
pGEM-T vector (Promega) containing the P1 fragment
f the FMDV O1C genome as a c-DNA (Piccone et al.,
npublished results). The primers vp1-Pac I (59 TTAAT-
AAATGACCACTTCTGCG 39) and vp1-Pme I (59 GTTTA-
ACTTACAAAGTCTGTTT 39) were used to introduced
tart and stop codons into the native sequence of VP1
long with PacI and PmeI restriction sites, respectively.
he amplified DNA was then inserted into the PacI and
meI restriction enzyme sites in the polylinker sequence
etween the mp and the cp genes of the TMV vector (Fig.
). The TMV-30B.VP1 plasmid was linearized by digestion
FIG. 4. Schematic diagram of the TMV-30B-based vector showing the
f the viral genes in the vector that encode the replicase (RNA-depend
he VP1 gene (0.64 kb) was inserted between the PacI and the PmeI sit
romoter sequence of the original cp gene. The locations of the cp sub
elated tobamovirus (stippled arrow) are indicated, as is the location oith KpnI (located downstream of the TMV genes) and ghen used as a DNA template for the in vitro production
f the infectious viral capped RNA (Ampliscribe T7 Tran-
cription Kit; Epicentre Technology), employing the bac-
eriophage T7 promoter placed upstream of the TMV
eplicase gene. Infectious RNA transcripts were diluted
n buffer containing 1% Na-pyrophosphate (pH 9.0), 1%
elite, and 1% bentonite and mechanically inoculated
nto N. benthamiana plants. Three leaves per plant were
noculated on the upper surface and plants were kept in
rowth chambers (16 h/day of light, 30°C day tempera-
ure, 24°C night temperature) until harvested.
estern blot analysis of the TMV.VP1-infected foliar
xtracts
The presence of the recombinant protein in the plants
nfected with TMV.VP1 was evaluated by Western blot
nalysis using a mouse antiserum specific for a syn-
hetic peptide containing the amino acid sequence lo-
ated between residues 135 and 160 of VP1 FMDV O1C
p135-160) (Zamorano et al., 1994). Leaf tissue (0.1 g) from
ock-, TMV.VP1-, and wild-type TMV (TMV.WT)-infected
lants was macerated in the presence of liquid nitrogen,
esuspended in 200 ml of sample buffer (50 mM Tris, pH
.5, 1 mM PMSF, 8 M urea, 1% SDS, 2 mM DTT, and 2%
-bME), and boiled for 10 min before electrophoresis in
2.5% SDS–PAGE. The gels were then blotted onto an
mmobilon P (Millipore) membrane which was blocked
vernight with PBS containing 0.05% Tween 20 (PBST)
ontaining 3% skim milk (all subsequent steps were
erformed using this buffer) and incubated with a mouse
ntiserum specific for p135-160 for 2 h at 37°C. The
embrane was then washed using PBST and incubated
ith an alkaline phosphatase-labeled anti-mouse Ig
n of the insert of the FMDV VP1 gene. The diagram shows the location
A polymerase), the movement protein (mp), and the coat protein (cp).
e polylinker sequence positioned just downstream of the subgenomic
ic promoter (white arrow) and a second subgenomic promoter from a
7 promoter and key restriction sites.positio
ent RN
es in th
genomuinea pig antiserum (Dakkopats) for 1 h at 37°C. After
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90 WIGDOROVITZ ET AL.hree washes the reaction was developed by the addition
f the substrate NBT/CIP.
nalysis of antibody response to plant-expressed VP1
olypeptides
Sera from the immunized mice were evaluated for the
resence of anti-FMDV-specific antibodies by ELISA and
estern blot.
ELISA. These were performed using as antigen either
he synthetic peptide p135-160 or purified FMDV parti-
les. In the case of p135-160, the peptide was adsorbed
irectly to the plate at a concentration of 15 mg/ml. To
etect anti-virus particle activity, purified FMDV particles
produced, inactivated, and purified as described in Ber-
nstein et al., 1991) were added to the plate (at a con-
entration of 1 mg/ml) to which the capturing antibody
ad been adsorbed. In either case, antigen incubation
as performed for 1 h at 37°C. Plates were then washed
hree times with PBST and blocked with 3% horse serum
n PBST for 2 h at 37°C (all subsequent steps were
erformed using this buffer). Mouse sera were tested in
fourfold dilution series in blocking buffer and incubated
or 1 h at 37°C. Plates were washed again and incubated
or 45 min at 37°C with peroxidase-labeled rabbit anti-
ouse Ig antibodies (Dakkopats). After five washes, the
eaction was developed by addition of o-phenylenedi-
mine–H2O2 in citrate buffer, pH 5, and read 3 min later
t 490 nm in an MR 500 microplate reader (Dynatech).
iters are expressed as log10 of the reciprocal of the
ighest serum dilution which gives OD readings above
he mean OD 1 3 SD of sera from five animals immu-
ized with plants infected with the TMV.WT vector.
Western blot. The procedure is basically the same as
escribed above for the detection of recombinant VP1
xpressed in plants infected with TMV.VP1. As antigen,
urified FMDV O1C particles (Berinstein et al., 1991)
ere used at a concentration of 0.5 to 1 mg/lane. Sera
ere used at 130 in blocking buffer.
hallenge experiments
Mice were challenged intraperitoneally (ip) with 104
uckling mouse lethal doses (SM50LD). Protection was
etermined by the absence of viremia in the challenged
ice at 36 h postinfection. Viremia was tested by intra-
uscular inoculation of 50 ml of a 110 dilution of peripheral
lood into each of six mice from a 5- to 6-day old litter per
lood sample. The inoculated litter was observed daily
or 1 week (Wigdorovitz et al., 1999).
ACKNOWLEDGMENTS
The authors thank Mrs. M. A. Palacios and Mr. F. Go´mez for technical
ssistance and the personnel of Laboratory Bayer in Argentina where
he challenge experiments were conducted. Dr. Roy French is thanked
or his help in the experimental design of the vector and Dr. W. O.awson for kindly supplying the modified TMV vector. This work wasupported by Grant BID 802/OC-AR PID 168 from SECYT-CONICET,
ep. Argentina, and by a grant from the UNL Center for Biotechnology.
REFERENCES
rakawa, T., Chong, D. K. X., and Langridge, W. H. R. (1998). Efficacy of
a food plant based oral cholera toxin B subunit vaccine. Nat. Bio-
technol. 16, 292–297.
rntzen, J. C., and Mason, H. S. (1995). Oral vaccine production in the
edible tissues of transgenic plants. In “New Generation Vaccines”
(M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Coban, Eds.), 2nd
ed., pp. 263–277. Dekker, New York.
erinstein, A., Piatti, P., Gaggino, O. P., Schudel, A. A., and Sadir, A. M.
(1991). Enhancement of the immune response elicited with foot-and-
mouth disease virus vaccines by an extract of the Mycobacterium sp.
wall. Vaccine 9, 883–888.
rown, F. (1992). Vaccination against foot and mouth disease virus.
Vaccine 10, 1022–1026.
arrillo, C., Wigdorovitz, A., Oliveros, J. C., Zamorano, P. I., Sadir, A. M.,
Go´mez, N., Salinas, J., Escribano, J. M., and Borca, M. V. (1998).
Protective immune response to foot-and-mouth disease virus with
VP1 expressed in transgenic plants. J. Virol. 72, 1688–1690.
alsgaard, K., Uttenthal, A., Jones, T. D., Xu, F., Merryweather, A.,
Hamilton, W. D., Langeveld, J. P., Boshuizen, R. S., Kamstrup, S.,
Lomonossoff, G. P., Porta, C., Vela, C., Casal, J. I., Meloen, R. H., and
Rodgers, P. B. (1997). Plant derived vaccine protects target animals
against a viral disease. Nat. Biotechnol. 15, 248–252.
iMarchi, R., Brooke, G., Gale, C., Cracknell, V., Doel, T., and Mowat, N.
(1986). Protection in cattle against foot and mouth disease by a
synthetic peptide. Science 232, 639–647.
onson, J., Kearney, C. M., Hilf, M. E., and Dawson, W. O. (1991).
Systemic expression of bacterial gene by a tobacco mosaic virus-
based vector. Proc. Natl. Acad. Sci. USA 88, 7204–7208.
o´mez, N., Carrillo, C., Parra, F., Salinas, J., Borca, M. V., and Escribano,
J. M. (1998). Expression of immunogenic glycoprotein S polypeptides
from transmissible gastroenteritis coronavirus in transgenic plants.
Virology 249, 352–358.
aq, T. A., Mason, H. S., Clements, J. D., and Arntzen, C. J. (1995). Oral
immunization with recombinant bacterial antigen produced in trans-
genic plants. Science 268, 714–716.
oelson, T., Akerblom, L., Oxelfelt, P., Strandberg, B., Tomenius, K., and
Morris, T. J. (1997). Presentation of a foreign viral peptide on the
surface of the tomato bushy stunt virus. J. Gen. Virol. 78, 1428–1435.
leid, D. G., Yansura, D., Small, B., Dowbenko, D., Moore, D. M.,
Grubman, M. J., McKercher, P. D., Morgan, D. O., Robertson, B. H.,
and Bachrach, H. L. (1981). Cloned viral protein vaccine for foot and
mouth disease: Responses in cattle and swine. Science 214, 1125–
1129.
umagai, M. H., Turpen, T. H., Weintzettle, N., Della Gioppa, G., Turpen,
A. M., Donson, J., Hilf, M. E., Gramtham, G. M., Dawson, W. O., Chow,
T. P., Piatak, M., Jr., and Grill, L. K. (1993). Rapid, high level expression
of biologically active alpha trichosanthin in transfected plants by an
RNA viral vector. Proc. Natl. Acad. Sci. USA 90, 427–430.
ason, H. S., Lam, D. M.-K., and Arntzen, C. J. (1992). Expression of
hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci.
USA 89, 11745–11749.
ason, H. S., Ball, J. M., Shi, J. J., Jiang, X., Estes, M. K., and Arntzen, C. J.
(1996). Expression of Norwalk virus capsid protein in transgenic
tobacco and potato and its oral immunogenicity in mice. Proc. Natl.
Acad. Sci. USA 93, 5335–5340.
ason, H. S., Haq, T. A., Clements, J. D., and Arntzen, C. J. (1998). Edible
vaccine protects mice against Escherichia coli heat labile entero-
toxin (LT): Potatoes expressing a synthetic LT-B gene. Vaccine 16,
1336–1443.
cGarvey, P. B., Hammond, J., Dienelt, M., Hooper, D. C., Fu, Z. F.,
Dietzschold, B., Koprowski, H., and Michaels, F. H. (1995). Expression
PP
P
T
T
U
W
Y
Z
Z
91PROTECTIVE IMMUNE RESPONSE TO FMDV IN MICEof rabies virus glycoprotein in transgenic tomatoes. Biotechnology
13, 1484–1487.
e´rez Filgueira, D. M., Berinstein, A., Smitsaart, E., Borca, M. V., and
Sadir, A. M. (1995). Isotype profiles induced in Balb/c mice during
foot and mouse disease (FMD) virus infection or immunization with
different FMD vaccine formulations. Vaccine 13, 953–960.
orta, C., Spall, S. E., Loveland, J., Johnson, J. E., Barker, P. J., and
Lomonossoff, G. P. (1994). Development of cowpea mosaic virus as
high-yielding system to the presentation for foreign peptides. Virol-
ogy 202, 949–955.
orta, C., Spall, S. E., Lin, T., Johnson, J. E., and Lomonossoff, G. P.
(1996). The development of cowpea mosaic virus as a potential
source of novel vaccines. Intervirology 39, 79–84.
acket, C. O., Mason, H. S., Losonsky, G., Clements, J. D., Levine, M. M.,
and Arntzen, C. J. (1998). Immunogenicity in humans of a recombi-
nant bacterial antigen delivered in a transgenic potato. Nat. Med. 4,
607–609.
urpen, T. H., Reinl, S. J., Charoenvit, Y., Hoffman, S. L., Fallarme, V., and
Grill, L. K. (1995). Malarial epitopes expressed on the surface of
recombinant tobacco mosaic virus. Biotechnology 13, 53–57.
sha, R., Rohll, J. B., Spall, V. E., Shanks, M., Maule, A. J., Johnson, J. E.,
and Lomonossoff, G. P. (1993). Expression of an animal virus anti-genic site on the surface of a plant virus particle. Virology 197,
366–374.
igdorovitz, A., Carrillo, C., Dus Santos, M., Trono, J. K., Peralta, A.,
Go´mez, M. C., Rı´os, R. D., Franzone, P. M., Sadir, A. M., Escribano,
J. M., and Borca, M. V. (1999). Induction of a protective antibody
response to foot and mouth disease virus in mice either orally or
parenterally immunized with alfalfa transgenic plants expressing the
viral structural protein VP1. Virology 255, 347–353.
usibov, V., Moldeska, A., Steplewski, K., Agadjanyan, M., Weiner, D.,
Hooper, D. C., and Koprowski, H. (1997). Antigens produced in plants
by infection with chimeric plant viruses immunize against rabies
virus and HIV-1. Proc. Natl. Acad. Sci. USA 94, 5784–5788.
amorano, P. I., Wigdorovitz, A., Ferna´ndez, F. M., Chaer, M., Marcov-
ecchio, F. E., Carrillo, C., Sadir, A. M., and Borca, M. V. (1994).
Recognition of T and B epitopes by cattle immunized with a synthetic
peptide containing the major immunogenic area of FMDV O1 Cam-
pos VP1. Virology 201, 383–387.
amorano, P., Wigdorovitz, A., Pe´rez-Filgueira, D. M., Escribano, J. M.,
Sadir, A. M., and Borca, M. V. (1998). Induction of an anti-foot and
mouth disease virus T and B cell response in cattle immunized with
a peptide representing 10 amino acids of VP1 subtype O1 Campos.
Vaccine 16, 558–563.
